Myomo (MYO) traded down -0.82 % during a 24 hours period ending at 07:58 PM Central Europe on Monday 26th. One Myomo stock can currently be bought for about USD 1.22 on popular exchanges. Current supply of Myomo stocks is 39.6 mn. Myomo has a current market capitalization of USD 47.9 mn and approximately USD 238.5 k worth of Myomo was traded on exchanges in the last 24 hours. Since last month end, Myomo has traded -27.54 % down. Simple moving average of last 200 days is at USD 1.07. The highest price of past 52 weeks was recorded at USD 1.88 on 08/19/2026. 52 weeks low was at USD 0.6 on 03/31/2026.

Here is how related stocks have performed in the past 24 hours:

  • Btcs (BTCS) traded down -1.82 % and now trades at USD 1.05. Current market capitalisation for Btcs is USD 56.7 mn. Summit Therapeutics announced that its partner Akeso’s Phase III HARMONi‑GI1 study, conducted exclusively in China, reported that ivonescimab combined with chemotherapy produced a statistically significant overall‑survival advantage over durvalumab plus chemotherapy in patients with advanced biliary tract cancer. The interim analysis highlighted improved survival and progression‑free survival, as well as higher response and disease‑control rates for the ivonescimab arm, while safety profiles were comparable between the two regimens. The company emphasized that this is the first Phase III trial in this disease to demonstrate such superiority and that the results reinforce the potential of ivonescimab across multiple tumour types. Summit also noted plans to launch a registration‑enabling Phase II/III study in collaboration with ECOG‑ACRIN later in 2026 to further evaluate the drug in the United States.

  • New Fortress Energy (NFE) traded down -1.97 % and now trades at USD 3.36. Current market capitalisation for New Fortress Energy is USD 56.8 mn.

  • Caribou Biosciences (CRBU) traded down -4.82 % and now trades at USD 0.5. Caribou Biosciences has a market capitalisation of USD 57.1 mn.

  • Heron Therapeutics (HRTX) traded flat 0 % and now trades at USD 0.3. Heron Therapeutics has a market capitalisation of USD 57.5 mn.

About Myomo

Myomo, Inc. is a medical robotics company operating in the Health Care Equipment & Supplies industry. The company is located in Cambridge, Massachusetts, USA. Its mission is to provide expanded mobility to individuals suffering from neurological disorders and upper-limb paralysis by restoring the function in their paralyzed and weakened arms and hands, which are often affected after suffering a stroke, spinal cord, or nerve injury. Myomo develops and markets arm braces as their primary product, which are available on their website (www.myomo.com ) and traded on the New York Stock Exchange. The IPO of Myomo Inc. took place on June 12, 2017.